(Q34030811)

30 July 2017

Etiology and management of pyoderma gangrenosum: a comprehensive review (English)

1 reference

30 July 2017

1 reference

Iris Ahronowitz

1

1 reference

30 July 2017

Joanna Harp

series ordinal

2

1 reference

30 July 2017

Kanade Shinkai

series ordinal

3

1 reference

30 July 2017

1 June 2012

1 reference

American Journal of Clinical Dermatology

30 July 2017

1 reference

30 July 2017

13

1 reference

30 July 2017

3

1 reference

30 July 2017

191-211

1 reference

https://scigraph.springernature.com/pub.10.2165/11595240-000000000-00000

30 July 2017

0 references

cites work

Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Ocular and extracutaneous involvement in pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Multiple aseptic pulmonary nodules with central necrosis in association with pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

The extracutaneous involvement in the neutrophilic dermatoses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Atypical pyoderma gangrenosum in a patient with osteomyelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Peristomal pyoderma gangrenosum and inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

The Shwartzman phenomenon: a review with a consideration of some possible dermatological manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

CONCERNING THE SPECIFICITY AND NATURE OF THE PHENOMENON OF LOCAL SKIN REACTIVITY TO VARIOUS BACTERIAL FILTRATES.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum: an updated review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Skin ulcers misdiagnosed as pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum: an Indian perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Primary sclerosing cholangitis and extraintestinal manifestations in patients with ulcerative colitis and ileal pouch-anal anastomosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Peripheral arthritis in the course of inflammatory bowel diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Mycophenolate mofetil as therapy for pyoderma gangrenosum.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosum in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Cutaneous manifestations in 404 Iranian patients with inflammatory bowel disease: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Skin lesions in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Parastomal pyoderma gangrenosum in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum: a report of 21 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pustular pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Leg ulceration in rheumatoid arthritis--an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Atypical bullous pyoderma gangrenosum associated with myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum in myelodysplasia and acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Systemic lupus erythematosus presenting as pyoderma gangrenosum in two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Cutaneous manifestations of systemic lupus erythematosus in a tertiary referral center

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Two percent topical phenytoin sodium solution in treating pyoderma gangrenosum: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum in pediatric acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Neutrophilic dermatosis of myeloproliferative disorders. Atypical forms of pyoderma gangrenosum and Sweet's syndrome associated with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Case reports and a review of the literature on ulcers mimicking pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Could your case of necrotising fascitis be Pyoderma gangrenosum?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Topical treatment of pyoderma gangraenosum.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum: a review and update on new therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Successful treatment of pyoderma gangrenosum with topical 0.5% nicotine cream

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Treating the chronic wound: A practical approach to the care of nonhealing wounds and wound care dressings

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Leg ulcers: uncommon presentations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Treatment of pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum: associations revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Therapy Insight: pyoderma gangrenosum-old disease, new management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Topical tacrolimus therapy for pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Topical tacrolimus in the management of peristomal pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Management of pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum--response to topical nitrogen mustard

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Clearing of Pyoderma gangrenosum by intralesional cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Treatment of pyoderma gangrenosum with cultured keratinocyte autografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

A rationale for adjuvant surgical intervention in pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Minimizing the risk of post-operative pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Management strategies for pyoderma gangrenosum: case studies and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Behçet's syndrome with pyoderma-gangrenosum-like lesions treated successfully with dapsone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Optimal treatment of pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Treatment of pyoderma gangrenosum with cyclosporine: results in seven patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Pyoderma gangrenosum--rebel without a cure?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Mycophenolate mofetil in pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595240-000000000-00000

10.2165/11595240-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference